METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS
The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit prote...
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English Spanish |
Published |
10.11.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.
La presente invención se refiere a métodos para prevenir, tratar o mitigar diabetes al administrar a un sujeto que necesita el mismo una cantidad terapéuticamente efectiva de antagonistas de D114 que bloquean las vías de señal de D114 - Notch. Como se observa en un modelo de diabetes en ratón, los antagonistas de D114 presentan efectos protectores sobre islotes pancreáticos, reducen los niveles de glucosa en la sangre, y bloquean la producción de auto-anticuerpos, incluyendo aquellos contra insulina y ácido glutámico descarboxilasa 65 (GAD65), mediante la expansión de células T reguladoras (Tregs). Por lo tanto, la presente invención además provee métodos para reducir los niveles de glucosa en la sangre, y/o reducir o bloquear la producción de auto-anticuerpos, al administrar a un sujeto que necesita el mismo una cantidad terapéuticamente efectiva de antagonistas de D114. Los antagonistas de D114 adecuados para la invención incluyen anticuerpos o fragmentos de anticuerpo que se unen específicamente a D114 y bloquean las interacciones D114 - Notch, el dominio extracelular de D114, y similares. |
---|---|
Bibliography: | Application Number: MX20120008638 |